Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Monthly Archives: November 2014

NJ Congressman Pallone Elected Ranking Member of House Energy & Commerce Committee

Washington, DC, November 20, 2014 ― The Star-Ledger reports that defeating a lawmaker backed by House Democratic Leader Nancy Pelosi, U.S. Representative Frank Pallone  (D-NJ-6) was chosen by his fellow Democrats on Wednesday to serve as ranking member of the House of Representatives’ powerful Energy and Commerce Committee in the next Congress.

Congressman Pallone prevailed over Rep. Anna Eshoo of California in the secret balloting. Eshoo had been endorsed by House Minority Leader Pelosi as well as the House Democratic Steering and Policy Committee. Continue reading

HINJ to Host Policy Forum ‘Life Sciences: Saving Lives, Saving Money’ November 21

New Brunswick, NJ, November 19, 2014 ― The HealthCare Institute of New Jersey (HINJ) invites you to join leaders of New Jersey’s health care community for a health policy forum entitled Life Sciences: Saving Lives, Saving Money” that will be held Friday, November 21 from 8:30 to 11:00 a.m. at Forsgate Country Club in Monroe Township.

The forum will present a discussion about how the life sciences not only saves lives, but also lowers health care costs.  Topics and speakers will include:

  • Chronic Disease Management: Helping Patients and Saving Money — Larry Hausner, Former Chief Executive Officer, American Diabetes Association
  • Patient Adherence: Staying Healthy and Avoiding Expenses — Murray Aitken, Executive Director, IMS Institute for Healthcare Informatics
  • Medical Innovation: Prevention, Cures and Cost Avoidance — Ken Zaentz, President and Chief Executive Officer, Alzheimer’s Association, Greater New Jersey Chapter
  • Wellness and Prevention: Living Healthier and Spending Less — Linda J. Schwimmer, J.D., Vice President, New Jersey Health Care Quality Institute

Admission is free, but seating is limited.  To RSVP, please click here.

Tufts: Cost to Develop, Get Approval for a New Drug Is $2.6 Billion

Boston, MA, November 18, 2014 ― Developing a new prescription medicine that gains marketing approval, a process often lasting longer than a decade, is estimated to cost $2,558 million, according to a new study by the Tufts Center for the Study of Drug Development.

The $2,558 million figure per approved compound is based on estimated:

  • Average out-of-pocket cost of $1,395 million
  • Time costs (expected returns that investors forego while a drug is in development) of $1,163 million

Estimated average cost of post-approval R&D—studies to test new indications, new formulations, new dosage strengths and regimens, and to monitor safety and long-term side effects in patients required by the U.S. Food and Drug Administration as a condition of approval—of $312 million boosts the full product lifecycle cost per approved drug to $2,870 million. All figures are expressed in 2013 dollars. Continue reading

Retiring Congressman Rush Holt to Head American Association for the Advancement of Science

Washington, DC, November 18, 2014 ― The Star-Ledger reports that U.S. Representative Rush Holt (D-NJ-12) will return to his science roots after his retirement from Congress and lead the world’s largest general scientific organization as chief executive officer.

Beginning in February, Holt will serve as the new CEO and executive publisher of the American Association for the Advancement of Science, a 166-year-old nonprofit which publishes some of the most-read scientific journals in the world, the association announced on Tuesday. Continue reading

R&D Council of NJ Presents 2014 Edison Patent Awards

Chatham, NJ, November 7, 2014 ― The Research & Development Council of New Jersey presented its 2014 Edison Patent Awards last evening at the Liberty Science Center in Jersey City, NJ.

This year’s Edison Patent Award winners are:

  • Immunomedics (Biotechnology)
  • TE Connectivity SubCom (Communication Technology)
  • Colgate-Palmolive (Consumer Products)
  • U.S. Army ARDEC (Defense)
  • NJIT (Enabling Technology)
  • Siemens Corporation, Corporate Technology (Energy)
  • BASF (Environmental)
  • Exxon Mobil Research & Engineering Company (Industrial Process)
  • Avaya Labs (Information Technology)
  • Honeywell (Materials Technology)
  • Merck & Co. (Pharmaceutical Process)
  • Novartis Pharmaceuticals Corporation (Pharmaceutical Formulation)
  • Alcatel-Lucent Bell Labs (Telecommunications) Continue reading

NJLSVA Hosts 2014 Life Sciences Vendors Procurement Conference at Rowan University; Presentations Posted Online

RESIZE Steve Sweeney and Dean Paranicas

HealthCare Institute of New Jersey (HINJ) President and CEO Dean J. Paranicas and Senate President Stephen Sweeney

New Brunswick, NJ, November 6, 2014 ― The New Jersey Life Sciences Vendors Alliance hosted its Annual Vendors Procurement Conference on October 28 at Rowan University.  Forty-five vendors attended with 11 companies exhibiting.

Guest speakers included:

  • New Jersey Senate President Stephen Sweeney
  • The Honorable Rob Andrews, former Member of Congress and Of Counsel, Dilworth Paxson
  • Ken Blank, Ph.D., Senior Vice President of Health Sciences, Rowan University. Continue reading